Sign inJoin waitlistJoin the waitlist

Kristen Spencer

Director, Phase I Developmental Therapeutics Program, Perlmutter Cancer Center · NYU Grossman School of Medicine

Credentials: · · · ·

History

Phase I Developmental Therapeutics Program · NYU Grossman School of Medicine
Present
NYU Grossman School of Medicine
Present
NYU Grossman School of Medicine
Present

Rutgers Robert Wood Johnson Medical School
2014–2017
Rutgers Robert Wood Johnson Medical School
2011–2013
Rutgers University
2007–2011

Research

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
JAMA Oncology · 2016 · 537 citations
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers
ESMO Open · 2022 · 289 citations
Biomarkers for Immunotherapy: Current Developments and Challenges
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2016 · First of 6 authors · 106 citations

Janice Mehnert
11 papers
Salma Jabbour
10 papers
Darren Carpizo
6 papers · 2 as a resident
Howard Hochster
6 papers
DA
David August
5 papers
Miral Grandhi
5 papers
Timothy Kennedy
5 papers
Ann Silk
4 papers
Christopher Lieu
4 papers
Eugenia Girda
4 papers
JM
Jyoti Malhotra
4 papers
Laura Goff
4 papers

Clinical trials

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2024–2028
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Principal investigator · Active not recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2020–2027
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Site PI · Recruiting · Phase 2
Verastem, Inc.
2026–2028
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Verastem, Inc.
2025–2028